Business Context and Reporting Period
This summary covers the Form 10-Q filed by Schering-Plough Corporation for the quarterly period ended June 30, 2006. The company operates in three segments: Prescription Pharmaceuticals, Consumer Health Care, and Animal Health. A significant portion of the company's financial performance is driven by its cholesterol franchise (VYTORIN and ZETIA) developed in a joint venture with Merck & Co., Inc., which is accounted for using the equity method.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2006 | Six Months Ended June 30, 2006 |
|---|---|---|
| Net Sales | $2,818 million | $5,369 million |
| Net Income (Loss) Available to Common Shareholders | $237 million | $587 million |
| Diluted EPS | $0.16 | $0.40 |
| Operating Cash Flow | N/A | $810 million |
| Equity Income from Cholesterol Joint Venture | $355 million | $666 million |
| Research & Development Expenses | $539 million | $1,020 million |
| Cash and Cash Equivalents (End of Period) | $1,842 million | $1,842 million |
| Total Debt (Short-term + Long-term) | $2,843 million | $2,843 million |
Note: Short-term borrowings were $430 million and long-term debt was $2,413 million as of June 30, 2006.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% ($286 million) for the quarter and 10% ($469 million) for the six months compared to the same periods in 2005. Growth was driven by REMICADE, NASONEX, and PEG-INTRON, partially offset by a 1% unfavorable foreign exchange impact.
- Profitability Turnaround: The company reported net income of $237 million for the quarter, a significant improvement from a net loss of $70 million in the second quarter of 2005. This turnaround is largely attributed to the strong performance of the cholesterol joint venture.
- Special Charges: Special charges decreased significantly to $80 million for the quarter (down from $259 million in Q2 2005). The 2006 charges relate to manufacturing streamlining (severance and asset impairments), whereas 2005 charges were primarily due to litigation reserves.
- Equity Income: Equity income from the cholesterol joint venture more than doubled to $355 million for the quarter and $666 million for the six months, reflecting strong sales of VYTORIN and ZETIA.
- Expense Increases: R&D expenses rose 22% for the quarter and 24% for the six months due to increased headcount and clinical trial costs. SG&A expenses increased 10% for the quarter.
Guidance, Outlook, and Risks
- Outlook: Management anticipates that sales from the cholesterol joint venture will grow in the second half of 2006. However, the company expects financial performance in the first half of 2006 to be stronger than the second half due to seasonal patterns and expected unfavorable comparisons for the hepatitis franchise in Japan.
- Manufacturing Streamlining: The company announced plans to close facilities in Manati, Puerto Rico, and reduce workforce in New Jersey, eliminating approximately 1,100 positions. Total expenses are expected to range from $250 million to $260 million, with anticipated annual savings of $100 million starting in 2007.
- Regulatory Risks: The company remains subject to an FDA Consent Decree regarding Good Manufacturing Practices (cGMP) at facilities in New Jersey and Puerto Rico. While revalidation programs are complete, third-party certification is pending. Failure to comply could result in additional payments.
- Legal Investigations: The company is under investigation by the U.S. Attorney's Office for the District of Massachusetts regarding sales and marketing practices. A liability of $500 million has been recorded. Other investigations include AWP pricing practices and NITRO-DUR classification.
- Accounting Changes: The company adopted SFAS 123R (Share-Based Payment) effective January 1, 2006, resulting in a $22 million cumulative income benefit in the first six months of 2006.
Investor Verification Checklist
- Cholesterol Franchise Dependency: Verify the sustainability of VYTORIN and ZETIA sales growth given the entry of generic competitors in the cholesterol market.
- Manufacturing Costs: Monitor the execution of the manufacturing streamlining plan and the realization of the projected $100 million in annual savings.
- Legal Reserves: Track the status of the Massachusetts investigation and AWP litigation to assess if the $500 million reserve is sufficient or if additional charges are likely.
- Consent Decree Status: Confirm the timeline for third-party certification of the cGMP Work Plan to avoid potential additional penalties under the FDA Consent Decree.
- R&D Pipeline: Evaluate the progress of key pipeline candidates (Thrombin Receptor Antagonist, vicriviroc, HCV protease inhibitor) given the significant increase in R&D spending.